EIP Pharma

As of August 2023, EIP Pharma is now CervoMed. For more information about the company, please visit and follow us @Cervo_Med on Twitter.

[EIP Pharma @EIP_Pharma]

EIP Pharma, Inc has merged with Diffusion Pharmaceuticals, and is now CervoMed. Please follow us on our new Twitter @Cervo_Med . For more information on the change, click here: https://t.co/tVrg44bSSD

[EIP Pharma @EIP_Pharma]

We’re happy to share EIP Pharma’s leadership will be presenting at the Canaccord Genuity’s 43rd Annual Growth Conference on Wednesday, August 9th at 4:00 p.m. ET, in Boston. Learn more here: https://t.co/ETq7KGSS8C

#CGDriven #GC2023 #DrivenByYourSuccess

[EIP Pharma @EIP_Pharma]

#DYK more than 55 million people are living with Alzheimer’s or another form of dementia? This month join us and @alzassociation and wear purple to raise awareness for the community. Learn more about ways to take action here: https://t.co/bE1h46b841

#ENDALZ

[EIP Pharma @EIP_Pharma]

This month is American Stroke Awareness Month. It’s important to recognize the signs of Stroke (F.A.S.T.) and call 9-1-1 immediately, if you or someone you know is experiencing any of these symptoms. Every minute counts!
#StrokeMonth

[EIP Pharma @EIP_Pharma]

#ICYMI: Our academic partners presented new MRI data in patients with #Alzheimers at #ADPD2023 last weekend. Learn more here: https://t.co/T0J3eV2dlA

[EIP Pharma @EIP_Pharma]

Grant from National Institute on Aging at NIH will fund our next clinical study with neflamapimod, a phase 2b study that is designed to confirm that positive findings in our phase 2a study in dementia with Lewy bodies https://t.co/H2RG2n7hTF

[EIP Pharma @EIP_Pharma]

Presentation of MRI data at CTAD conference demonstrates potential of neflamapimod to positively impact the cholinergic degenerative process in early Alzheimer’s Disease #Dementia #AlzheimersDisease. Read more:
https://t.co/EddIYeaNHf

[EIP Pharma @EIP_Pharma]

Thanks to @NatureComms for recognizing our publication on translational results for #neflamapimod in its Editors’ Highlights “From brain to behaviour” which showcases the most exciting work on the brain in Nature Communications
https://t.co/LbYCrJiC1S

[EIP Pharma @EIP_Pharma]

Thanks to @Anjali_Sarkar and @GENbio for the coverage of our recent publication.
https://t.co/BhuVpgxajJ

https://t.co/t0YasSsuws

[Anjali A. Sarkar, PhD @Anjali_Sarkar]

Stereological cell counting, electrophysiology and behavioral tests enable scientists at @EIP_Pharma & @nyugrossman to show that a #kinase-inhibitor benefits patients with #dementia with Lewy bodies.
https://t.co/iSLms4u7qZ

[EIP Pharma @EIP_Pharma]

Preclinical data on neflamapimod’s MOA coupled with early clinical data suggest potential efficacy in treating root cause of DLB. See today’s paper:
#Dementia #Lewybodies @NatureComms
https://t.co/nfX7HGNx5K

[EIP Pharma @EIP_Pharma]

EIP Pharma Co-Founder, President and CEO John Alam commented on neflamapimod’s potential, if approved, as first treatment for DLB (@NatureComms):
https://t.co/nfX7HGNx5K
#Dementia #LewyBodies

[EIP Pharma @EIP_Pharma]

Translational results were published in @NatureComms by EIP Pharma from preclinical work to a Phase 2a trial showing potential to improve cognition and motor function for patients with #Dementia #LewyBodies. Read more: https://t.co/qwuz6ORZ5f

[Boston Business Journal @BosBizJournal]

Startup aims to give castoff Vertex drug new life as Alzheimer’s treatment https://t.co/5pvmbX4BHY

[EIP Pharma @EIP_Pharma]

Good article from @FierceBiotech about our new financing. https://t.co/BGmN7NHESR

[FierceBiotech @FierceBiotech]

With neflamapimod, EIP is hoping to reverse synaptic dysfunction and not just arrest or delay it, although as with any biopharma in this space, history is not on its side: https://t.co/pn42bRn3gF

[EIP Pharma @EIP_Pharma]

Today we announced that we secured $20.5 million in Series B financing. #AlzheimersDisease Read more here. https://t.co/UGDGcZnwVe

[EIP Pharma @EIP_Pharma]

We are new to Twitter! Follow us here for company news, announcements and perspectives. #Alzheimers